Prolor Biotech reported positive preclinical results from an animal study of its long-acting obesity/Type II diabetes drug candidate MOD-6030. During the trial, the drug was administered to diet-induced obese mice once weekly over a 30-day period. According to Prolor, the results demonstrated efficacy in reducing weight, lowering blood glucose levels, increasing insulin sensitivity and reducing cholesterol levels as compared to a group that received placebo.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts

Clean Energy Company That Mimics The Sun Raises $22M
February 02, 2023

Blood Test Offers Hope For Lung Cancer Patients
February 02, 2023

Israel Opens Its First Satellite Observatory
February 02, 2023

Cloud Data-Securing Startup Raises $30M
February 01, 2023
Facebook comments